An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

OBJECTIVES:The objective of this analysis is to perform an indirect comparison of elvitegravir, cobicistat, emtricitabine and tenofovir DF (E/C/F/TDF) to abacavir/lamivudine and dolutegravir (ABC/3TC + DTG) by using 2 trials evaluating each of these regimens in comparison to efavirenz, emtricitabine...

Full description

Bibliographic Details
Main Authors:	Josep M Llibre, François Raffi, Graeme Moyle, Georg Behrens, Stephane Bouee, Geraldine Reilly, Peter Borg, David Piontkowsky, Felipe Rogatto
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4872996?pdf=render

Similar Items

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Iatrogenic Adrenal Insufficiency Secondary to Combination Therapy with Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Interlaminar Triamcinolone Injection in an AIDS Patient
by: Chanie Wassner PharmD, BCCCP, et al.
Published: (2017-11-01)

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review
by: Mark J. Naccarato BSc Pharm, et al.
Published: (2018-01-01)

Evaluation of urinary excretion of dolutegravir or emtricitabine/tenofovir/elvitegravir/cobicistat antiretroviral-based regimens using plasma and urine trough concentration
by: Jérémy Lourenco, et al.
Published: (2018-05-01)

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
by: Prinapori R, et al.
Published: (2015-08-01)

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
by: Nicola Squillace, et al.
Published: (2017-01-01)

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
by: Marianne Harris, et al.
Published: (2017-11-01)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and HBV co-infection
by: Y.-S. Huang, et al.
Published: (2019-07-01)

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar
by: Hussam Al Soub, et al.
Published: (2020-01-01)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
by: Wissam K. Kabbara, et al.
Published: (2015-09-01)

New simple spectrophotometric method for determination of the antiviral mixture of emtricitabine and tenofovir disoproxil fumarate
by: Heba K. Ashour, et al.
Published: (2017-05-01)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
by: Juday T, et al.
Published: (2013-09-01)

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
by: Allison Martin, et al.
Published: (2011-01-01)

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2012-01-01)

Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance
by: Yu-Yu Hsiao, et al.
Published: (2021-08-01)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
by: Lucia Taramasso, et al.
Published: (2019-01-01)

Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
by: Laura Waters, et al.
Published: (2021-03-01)

Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications
by: Rui Ma, et al.
Published: (2020-12-01)

HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases
by: S. Lena Kang-Birken PharmD, et al.
Published: (2019-01-01)

Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
by: Nicholas T Funderburg, et al.
Published: (2013-01-01)

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
by: Heon Ju Lee, et al.
Published: (2018-01-01)

A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
by: Graeme J Moyle, et al.
Published: (2015-01-01)

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study
by: Inés Suárez-García, et al.
Published: (2020-07-01)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
by: Saye H. Khoo, et al.
Published: (2011-06-01)

Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures.
by: Priya Srinivasan, et al.
Published: (2016-01-01)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
by: Chanie Wassner PharmD, BCCCP, BCIDP, et al.
Published: (2020-04-01)

Liquid chromatography metabolite profiling of tenofovir disoproxil fumarate
by: Kokil Sachin, et al.
Published: (2009-01-01)

The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01)

Development and Validation of UV-Visible Spectrophotometric Baseline Manipulation Method for Simultaneous Quantitation of Tenofovir Disoproxil Fumarate and Emtricitabine in Pharmaceutical Dosage Form
by: Vishnu P. Choudhari, et al.
Published: (2013-01-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya
by: Owino F, et al.
Published: (2013-11-01)

Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
by: Bruno Emond, et al.
Published: (2021-06-01)

Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
by: Bruno Emond, et al.
Published: (2021-06-01)

Effects of Hydrochlorothiazide on Tenofovir Disoproxil Fumarate-Induced Nephrotoxicity in Rats
by: Iman G.Al-Rakhat, et al.
Published: (2019-12-01)

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
by: J Jones, et al.
Published: (2010-05-01)

Formulation, development and assessment of tenofovir disoproxil fumarate-loaded pellets
by: Dube, Tawanda
Published: (2015)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
by: Andrew Hill, et al.
Published: (2018-04-01)